Veeva Systems Inc. 2027 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Veeva Systems reported fiscal 2027 second quarter total revenue of $928 million and non-GAAP operating income of $416 million, exceeding guidance.
- The commercial segment delivered record results with commercial subscriptions up about 13% year over year, excluding Crossix showing double-digit growth.
- Veeva secured two top 20 biopharma wins for Vault CRM in the quarter, including Lilly and Biogen, with confidence in winning the remaining two top 20 commitments by year-end.
- The company highlighted strong execution in CRM, content, data, and Crossix, with broad-based growth across commercial offerings.
- Veeva's AI product Veeva Falcon generated high customer interest, with five early adopters and first go-live expected this year, emphasizing faster implementation and cost savings.
- The Aspen startup within Veeva is focused on a new horizontal CRM built on modern technology with a simple pricing model, currently in early stages with early adopter customers.
- Veeva's partnership with IQVIA is progressing well, with both companies pleased and customers appreciating reduced hassle.
- China operations are growing profitably with products tailored for the China market that synergize with global offerings.
- R&D subscription revenue is transitioning from legacy products to newer strategic products like Koa, TSM safety, and LIMS, with strong long-term growth prospects.
- Consulting and services are benefiting from tech-enabled approaches that improve implementation speed and customer success, supporting application growth.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to the Veeva Systems fiscal 2027 second quarter results conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Gunnar Hansen, senior director, investor relations.
Gunnar, please go ahead. Good afternoon, and welcome to Veeva's fiscal 2027 second quarter earnings conference call for the quarter ended July 31st, 2026.
As a reminder, we posted prepared remarks on Veeva's investor relations website just after 1:00 P.M. Pacific today. We hope you've had a chance to read them before the call. Today's call will be used primarily for Q&A. With me today for Q&A are Peter Gassner, our chief executive officer, Paul Shawah, EVP, strategy, and Brian Van Wagener, our chief financial officer. During this call, we may make forward-looking statements regarding trends or strategies and the anticipated performance of the business, including guidance regarding future financial results. These forward-looking statements will be based on our current views and expectations and are subject to various risks and uncertainties. Our actual results may differ materially.
Please refer to the risks listed in our earnings release and the risk factors included in our most recent filing on Form 10-Q. Forward-looking statements made during the call are being made as of today, August 26th, 2026, based on the facts available to us today. If this call is replayed or reviewed after today, the information presented during the call may not contain current or accurate information. Veeva disclaims any obligation to update or revise any forward-looking statement. We may discuss guidance on today's call, but we will not provide any further guidance or updates on our performance during the quarter unless we do so in a public forum.
On the call, we may also discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A reconciliation to comparable GAAP metrics can be found in today's earnings release and in the supplemental investor presentation, both of which are available on our website. With that, thank you for joining us, and I'll turn the call over to Peter.
Thank you, Gunnar, and welcome everyone to the call. Q2 was another strong quarter, delivering results ahead of our guidance. Total revenue in the quarter was $928 million, with non-GAAP operating income of $416 million. Execution was exceptional this quarter as we made strong progress in many key areas. It was our best CRM quarter ever. We also are accelerating rapidly in AI overall, and especially with Veeva Falcon. Our focused acquisition strategy is working, bringing great people and capabilities to Veeva. It's an exciting time. AI is enabling the next big chapter for Veeva and the industry. We'll now open up the call to your questions.
We will now begin the question and answer session. Please limit yourself to one question and one follow-up. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Joe Vruwink with Baird. Joe, your line is now open.
Great. Thank you for the time today. I think it's evident over the past few months that biopharma R&D spending is headed in a positive direction, and that also is showing up at Veeva. As pipelines move forward, what are you finding the mentality to be at customers around assessing and adopting something that's brand new with thinking about the Vault Application Agents or even Veeva Falcon? I'm interested in levels of early interest taking place amidst what seems like a busier environment, and whether that's a reflection of the value customers are seeing pretty quickly when they start looking at the new Veeva offerings.
I'll take that one. Yeah, there are a lot of things going on, right? The funding environment is relatively good. There's a lot of changes with AI and sciences moving ahead, so there's a lot of priorities for the customers. When that happens, they can't do all things at once, and they generally try to pick some things that they can do and that are high priority. Your question was related to Falcon. I think Falcon has a lot of interest right now because it's very clear that that's high priority. Quick cost savings and compliance and efficiency. That's high on everybody's priority. I think there's a lot of interest in Falcon. We're the rate limiter right now. We have to get that product ready, start working with the early adopters, but interest in Falcon is very high.
That's great. And then maybe as you think about how customers can now engage with Veeva in an AI framework, you have the application agents, you have Falcon, you have a custom development framework that you've introduced. Are any of those modes of engagement maybe becoming larger or a bigger piece of the conversation? Do any of those modes matter more or less as you think about how your financial model evolves and what the impact might end up being to Veeva?
Yes, it is a major change for Veeva. Falcon is agentic labor. That's something different than we've done before. We've done cloud software, data consulting. Now we have this fourth thing, agentic labor. It is transforming the discussion. There's two different things you could do with Veeva. You can do some agentic labor, you can do core applications. That was never the case before. The important point is Veeva, it fits very well. It's a structural advantage for Veeva to both have the agentic labor across multiple areas in life sciences, and have the core applications across multiple of those areas in life sciences. That's why I feel like we're very well-positioned, and the conversations are very rich. Gosh, I just hope we got to get that product going as soon as we can.
If we had our early adopters live and successful right now, I don't want it be hyperbole, but Falcon would be flying off the shelf if that was the case. One thing to know is there's not an extensive Falcon implementation. There's not a data mapping from one system to the other. There's not a cut-over process. There's not ETL to do. This implementation, the full value is faster with Falcon, but the tech underneath it is newer, and we have to get our motion down there. If you can tell, I hope you can tell, I'm pretty excited about Falcon. I really think we're onto something.
That's great. Thank you. Your next question comes from the line of Brian Peterson with Raymond James.
Brian, your line is now open.
Hey, gentlemen. Thanks for taking the question, and congrats on a strong quarter. The commercial segment was really strong this quarter. I know you called out record results. Could you maybe unpack what drove that acceleration in the subscription line item? Would love to get some more color there.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
22 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
